EADV 2018: The Anti–IL-36 Receptor Antibody 655130 Appears Safe and Effective in Acute Generalized Pustular Psoriasis
Blockade of the IL-36 pathway with a single IV dose of BI 655130 was highly effective and well tolerated.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.